Iterum Therapeutics Plc
(NASDAQ : ITRM)

( )
ITRM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.17%60.590.0%$1954.52m
REGNRegeneron Pharmaceuticals, Inc. -0.95%598.542.5%$1194.19m
GILDGilead Sciences, Inc. 4.22%77.541.0%$991.43m
AMGNAmgen, Inc. -0.05%220.881.3%$628.89m
NVAXNovavax, Inc. 0.93%44.66102.0%$620.64m
VRTXVertex Pharmaceuticals, Inc. -1.51%272.821.9%$540.62m
ILMNIllumina, Inc. 0.02%358.403.5%$384.32m
BIIBBiogen, Inc. -0.98%299.651.6%$368.00m
ALXNAlexion Pharmaceuticals, Inc. -0.08%113.682.0%$250.86m
SRNESorrento Therapeutics, Inc. -6.76%3.861.8%$246.90m
SGENSeattle Genetics, Inc. -2.98%150.436.1%$229.28m
AAgilent Technologies, Inc. 0.70%91.121.6%$215.04m
BMRNBioMarin Pharmaceutical, Inc. -3.33%107.514.3%$187.14m
MGNXMacroGenics, Inc. -2.52%20.486.2%$164.68m
INCYIncyte Corp. -5.09%93.802.5%$153.77m

Company Profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.